Search for: [Abstract = "Depression is a severe mental condition, and according to the World Health Organization is now the second most common cause of disability in the world, and it will probably take the lead in 2030. Despite the high prevalence, reaching over 264 million people worldwide, we still do not have 100% effective treatment. Moreover, the drugs are still ineffective in around one\-third of depressed individuals. One of the reasons for drug therapeutic failure may be low compliance and adherence – patients often discontinue therapy due to delayed onset of action of most antidepressants and many side effects, as well as the comorbidities. The depressed patients often suffer from cognitive disorders, that worsen the clinical course of the disease, increase the risk of relapse and the occurrence of residual symptoms. Unfortunately, despite their significance in depression, memory impairments are often overlooked when designing new drugs. Hence, there is an urgent need to find new antidepressants that will treat not only affective symptoms but also cognitive decline. Previous studies have shown that HBK\-15 \(1\-\[\(2\-chloro\-6\- methylphenoxy\)ethoxyethyl\]\-4\-\(2\-methoxyphenyl\)piperazine hydrochloride\) possesses promising antidepressant\-like activity in animal models of depression, reversing both behavioral and molecular changes. Additionally, this compound showed memory\-enhancing proper"]

Number of results: 1